NATCO Pharma receives USFDA approval for Lenalidomide capsules
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
The company will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
Subscribe To Our Newsletter & Stay Updated